OCUL (Ocular Therapeutix) E10: $-1.94 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCUL Ocular Therapeutix Inc OCUL
55 GF Score
Price $11.30
GF Value $4.56
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocular Therapeutix E10?

Ocular Therapeutix OCUL -3.79% 55 E10 is $-1.94 as of Jun. 2026. GuruFocus rates OCUL with a GF Score™ of 55/100 and a GF Value™ of $4.56 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ocular Therapeutix's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.350. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.94 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 11.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Ocular Therapeutix was 11.50% per year. The lowest was 11.50% per year. And the median was 11.50% per year.

As of today (2026-08-20), Ocular Therapeutix's current stock price is $11.295. Ocular Therapeutix's E10 for the quarter that ended in Jun. 2026 was $-1.94. Ocular Therapeutix's Shiller PE Ratio of today is .


Ocular Therapeutix  (NAS:OCUL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ocular Therapeutix E10 Related Terms


Ocular Therapeutix E10 Historical Data

* Premium members only.

The historical data trend for Ocular Therapeutix's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix E10 Chart

Ocular Therapeutix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -2.78 -2.49 -1.97 -1.93

Ocular Therapeutix Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.98 -1.97 -1.93 -1.95 -1.94

OCUL vs KARD, GHRS, FTRE: E10 Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Shiller PE Ratio falls into.


OCUL
55GF Score
Ocular Therapeutix Inc OCUL
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocular Therapeutix E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ocular Therapeutix's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.35/333.9520*333.9520
=-0.350

Current CPI (Jun. 2026) = 333.9520.

Ocular Therapeutix Quarterly Data

per share eps CPI Adj_EPS
201609 -0.390 241.428 -0.539
201612 -0.520 241.432 -0.719
201703 -0.580 243.801 -0.794
201706 -0.640 244.955 -0.873
201709 -0.540 246.819 -0.731
201712 -0.440 246.524 -0.596
201803 -0.400 249.554 -0.535
201806 -0.370 251.989 -0.490
201809 -0.380 252.439 -0.503
201812 -0.420 251.233 -0.558
201903 -0.450 254.202 -0.591
201906 -0.570 256.143 -0.743
201909 -0.450 256.759 -0.585
201912 -0.530 256.974 -0.689
202003 -0.410 258.115 -0.530
202006 -0.640 257.797 -0.829
202009 -0.210 260.280 -0.269
202012 -1.210 260.474 -1.551
202103 -0.240 264.877 -0.303
202106 -0.250 271.696 -0.307
202109 -0.230 274.310 -0.280
202112 -0.230 278.802 -0.275
202203 -0.220 287.504 -0.256
202206 -0.250 296.311 -0.282
202209 -0.310 296.808 -0.349
202212 -0.240 296.797 -0.270
202303 -0.390 301.836 -0.431
202306 -0.260 305.109 -0.285
202309 -0.250 307.789 -0.271
202312 -0.350 306.746 -0.381
202403 -0.490 312.332 -0.524
202406 -0.260 314.175 -0.276
202409 -0.220 315.301 -0.233
202412 -0.290 315.605 -0.307
202503 -0.380 319.799 -0.397
202506 -0.390 322.561 -0.404
202509 -0.380 324.800 -0.391
202512 -0.290 324.054 -0.299
202603 -0.400 330.213 -0.405
202606 -0.350 333.952 -0.350

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.94 mean?
Ocular Therapeutix (OCUL) has a E10 of $-1.94 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors.
Is Ocular Therapeutix's E10 too high?
Ocular Therapeutix's current E10 is $-1.94. Overall, Ocular Therapeutix has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's E10 compare to KARD and GHRS?
Ocular Therapeutix's E10 of $-1.94 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors. Ocular Therapeutix's current E10 is $-1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (OCUL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.56, compared to a current price of $11.30 — trading 147.7% above its estimated fair value. The current E10 is $-1.94. Ocular Therapeutix's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Ocular Therapeutix (OCUL), the current E10 is $-1.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocular Therapeutix (OCUL) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of $11.30 is trading 147.7% above its estimated GF Value™ of $4.56. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for OCUL:

  • E10: $-1.94
  • GF Value™: $4.56 vs. price of $11.30 (147.7% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the OCUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges 0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
55GF Score

Get the complete analysis for OCUL

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.30
Price
$4.56
GF Value